HK Stock Market Move | LAEKNA-B(02105) rose by more than 6%, with industry insiders estimating that the peak sales of LAE002 in the Chinese market could reach 2 billion yuan.

LAEKNA-B (02105) rose more than 6%, reaching a gain of 4.92% at the time of publication, trading at 17.27 Hong Kong dollars, with a turnover of 321.93 million Hong Kong dollars. In terms of news, on November 12, Laekna Pharmaceuticals announced that it has granted the Chinese regional rights of its breast cancer candidate new drug LAE002 (afuresertib) to Qilu Pharmaceuticals, with a total agreement amount of up to 2.045 billion yuan. In addition to the upfront payment, Laekna Pharmaceuticals will also receive a 10%-20% sales tiered share, providing sufficient funding for its future research and development. This transaction is one of the larger-scale authorization collaborations in the domestic biopharmaceutical field this year. It is reported that LAE002 is a potent AKT inhibitor. In the HR+/HER2- breast cancer indication field, its global research and development progress ranks second only to AstraZeneca's Capivasertib. Industry experts estimate that LAE002 has the potential to reach sales peak of 2 billion yuan in the Chinese market, while its global market performance can refer to Capivasertib with estimated sales of 700-800 million US dollars this year, and a sales peak expected to exceed 1-2 billion US dollars.